Sargent Investment Group LLC Cuts Stock Position in Avid Bioservices, Inc. (NASDAQ:CDMO)

Sargent Investment Group LLC cut its stake in shares of Avid Bioservices, Inc. (NASDAQ:CDMO) by 1.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 712,505 shares of the biopharmaceutical company’s stock after selling 8,456 shares during the quarter. Avid Bioservices accounts for about 1.0% of Sargent Investment Group LLC’s investment portfolio, making the stock its 27th largest holding. Sargent Investment Group LLC owned approximately 1.13% of Avid Bioservices worth $4,631,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. CWM LLC raised its position in Avid Bioservices by 3,125.0% during the 4th quarter. CWM LLC now owns 6,708 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 6,500 shares during the last quarter. Advisor Partners II LLC bought a new position in Avid Bioservices during the 3rd quarter valued at approximately $98,000. Aigen Investment Management LP bought a new position in Avid Bioservices during the 3rd quarter valued at approximately $253,000. Mirae Asset Global Investments Co. Ltd. raised its position in Avid Bioservices by 19.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,761 shares of the biopharmaceutical company’s stock valued at $265,000 after purchasing an additional 6,745 shares during the last quarter. Finally, Fox Run Management L.L.C. bought a new position in shares of Avid Bioservices in the 3rd quarter worth approximately $267,000. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

Avid Bioservices Stock Up 0.4 %

Shares of NASDAQ:CDMO traded up $0.03 during trading on Friday, hitting $7.35. The stock had a trading volume of 1,268,426 shares, compared to its average volume of 952,830. Avid Bioservices, Inc. has a 12 month low of $4.07 and a 12 month high of $18.86. The company has a market capitalization of $466.58 million, a PE ratio of -27.22 and a beta of 1.63. The firm’s fifty day moving average is $7.01 and its 200 day moving average is $6.53. The company has a quick ratio of 0.85, a current ratio of 0.46 and a debt-to-equity ratio of 0.04.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 target price on shares of Avid Bioservices in a research report on Thursday, March 7th. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.25.

About Avid Bioservices

Avid Bioservices, Inc, a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support.